Inicio
Entrar
Ayuda
Buscar en este sitio:
Ensayos Registrados
Por tipo de intervención
Por estado de reclutamiento
Por promotor
Por fecha de registro
Búsqueda avanzada de ensayos
Proceso de Registro
Para registrar un ensayo
Formulario del Promotor
Formulario de ensayos del RPCEC
Para actualizar un ensayo registrado
Para reportar los resultados de un ensayo registrado
Inicio
|
Curmeric- Safety-Efficacy- Community-Quarantine-COVID-19
View current
Revisiones
List all revisions
Ver
Compare to current
22 Enero 2021 - 4:48pm
por Gladys
24 Marzo 2023 - 8:19am
por Gladys
Cambios a
Health condition(s) code
-
+
Disease Prevention
+
Coronavirus Infections
+
SARS Virus
+
Coronaviridae Infections
+
Nidovirales Infections
+
Betacoronavirus
Cambios a
Health condition keyword
+
COVID-19
+
SARS-CoV2
Cambios a
Intervention code
-
+
Curcuma
+
Administration, Oral
+
Plant Extracts
Cambios a
Intervention keyword
-
+
mouthwashes,
+
gargles
Cambios a
Record Verification Date
-
2021/01/
22
+
2021/01/
25
Cambios a
Next update date
-
2022/01/
22
+
2022/01/
25
Revisión de 24 Marzo 2023 - 8:19am
Curmeric- Safety-Efficacy- Community-Quarantine-COVID-19
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Scientific title:
Safety and efficacy study of the natural product Curmeric in a quarantined community of primary care due to possible cases of COVID-19.
Secondary indentifying numbers:
Not applicable
Issuing authority of the secondary identifying numbers:
Not applicable
Primary sponsor:
Center for Technological Applications and Nuclear Development (CEADEN)
Secondary sponsor:
General Calixto Garcia University Hospital
Source(s) of monetary or material support:
Center for Technological Applications and Nuclear Development (CEADEN) University Hospital General Calixto Garcia Ministry of Public Health
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Only approved by Ethics Committees
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Jorge
Last name:
Torres Concepcion
Medical Specialty :
Specialist of first grade of Medicine General Integrative, Mc.S. Infectious diseases
Affiliation:
Polyclinic Lidia y Clodomira
Postal address:
Retoria corner Enlace. Municipality Regla
City:
Havana
País:
Cuba
Zip Code:
11200
Telephone:
+53-77944441
Email address:
gmsregla@infomed.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Polyclinic Rampa, Raciel Vazquez Arceo. MD, Specialist of first grade of General Integrative Medicine
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Complete
Date of first enrollment:
03/10/2020
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
COVID-19
Health condition(s) code:
Disease Prevention
Coronavirus Infections
SARS Virus
Coronaviridae Infections
Nidovirales Infections
Betacoronavirus
Health condition keyword:
COVID-19
SARS-CoV2
Intervention(s):
Group I, Curmeric. Natural product that contains extracts of Curcuma longa -in intellectual property process- (oral) gargle (4mL) 3 times a day for a month. The group I included, the blocks of the primary health care area identified as a COVID-19 focus. Group II. They did not receive any product. The group included the blocks of the same health area that were not classified as COVID-19 focus.
Intervention code:
Curcuma
Administration, Oral
Plant Extracts
Intervention keyword:
mouthwashes, gargles
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Number of positive cases for COVID-19 (Number of positive patients). Measurement time: A month after inclusion
Key secondary outcomes:
Adverse Events-AE (Occurrence of AE (Yes, No); Type of event (name of AE); Intensity of AE (Mild, Moderate, Severe); Result (Recovered, Not recovered, Recovered with sequelae, Death); Required treatment (Yes, No)). Measurement time: A month after inclusion
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
5 years
Maximum age:
85 years
Inclusion criteria:
Inhabitants of the area in quarantine because of COVID-19 in primary health care.
Exclusion criteria:
Known allergy to Turmeric.
Type of population:
Children/Adults
Type of participant:
Healthy volunteers
Study design
Section to complete information about the characteristics of the study design.
Type study:
Observational
Purpose:
Prevention
Allocation:
Non-randomized controlled trial
Masking:
Open
Control group:
No intervention
Study design:
Parallel
Phase:
N/A
Target sample size:
340
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Tania
Last Name:
Valdes Gonzalez
Specialty:
Pharmaceutical Sciences, PhD
Affiliation:
Center for Technological Applications and Nuclear Development (CEADEN)
Postal Address:
Street 30th and 5ta Avenue. Municipality Playa
City:
Havana
País:
Cuba
Zip Code:
11300
Telephone:
+53-72021518
Email :
taniajapon@gmail.com
taniavaldes@infomed.sld.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Tania
Last Name:
Valdes Gonzalez
Specialty:
Pharmaceutical Sciences, PhD
Affiliation:
Center for Technological Applications and Nuclear Development (CEADEN)
Postal Address:
Street 30th and 5ta avenue. Playa
City:
Havana
País:
Cuba
Zip Code:
11300
Telephone:
+53-72021518
Email :
taniajapon@gmail.com
taniavaldes@infomed.sld.cu
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
General Calixto Garcia University Hospital
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
02/09/2020
Postal address of Ethic Committee :
Avenue Universidad and street J. Revolution Square. Havana, ZC:10400, Cuba
Telephone:
+53-78382171
Correo electrónico:
secdircg@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Final enrolment number:
340
Study completion date:
26/11/2020
Date of available results:
01/03/2021
Date of first publication:
01/04/2021
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000351
Date of Registration in Primary Registry:
22/01/2021
Record Verification Date:
2021/01/25
Next update date:
2022/01/25
Link to the spanish version:
Click here
Acerca del RPCEC
Estructura y Gobernanza
Política
Publicaciones
Reconocimientos
Comunicaciones
Noticias
Recursos útiles
Fundamentos del registro
Bibliografías en ensayos clínicos
Regulaciones cubanas
Otros registros
Plataforma Internacional de Registros de Ensayos Clínicos